Event rates and risk factors for venous thromboembolism and major bleeding in a population of hospitalized adult patients with acute medical illness receiving enoxaparin thromboprophylaxis

Venous Thromboembolism (VTE) related morbidity in patients hospitalized with acute medical illness may account for over 50 % of the overall burden of VTE. [1–7] Several randomized controlled trials (RCTs) have shown that thromboprophylaxis reduces the risk of VTE in this population while increasing the risk of bleeding[8–9]. Clinical practice guidelines recommend inpatient thromboprophylaxis as the overall benefit-risk remains favorable, especially in populations at high predicted risk for VTE and/or low predicted risk of bleeding.